In a multicenter , open-label , randomized , phase III study ( NCT00471965 ) , 371 patients ( 279 patients from the People 's Republic of China ) were randomized 1:1 to receive either FOLFOX4 or doxorubicin until disease progression , intolerable toxicity , death , or surgical resection .